

# ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,

Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : [info@kamronlabs.in](mailto:info@kamronlabs.in) Website: [www.kamronlabs.com](http://www.kamronlabs.com)

CIN : L24231GJ1988PLC010956



14<sup>th</sup> February, 2022

**BSE Limited**

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort,

Mumbai - 400 001

**Company Code No. 524604**

Dear Sirs,

**Sub: - Outcome of Board Meeting**

**- Submission of Unaudited Financial Results for the Quarter ended on 31<sup>st</sup> December, 2021**

We refer to our letter dated 29<sup>th</sup> January, 2022 informing the date of Meeting of the Board of Directors of the Company. Please note that the Board of Directors in their meeting held today i.e. on 14<sup>th</sup> February, 2022, have taken on record the Unaudited Financial Results for the quarter ended on 31<sup>st</sup> December, 2021.

We are enclosing herewith copy of the said Unaudited Financial Results for the quarter ended on 31<sup>st</sup> December, 2021 along with Limited Review Report thereon.

This is as per Regulation – 33 of the SEBI (LODR) Regulations, 2015.

Thanking you,

Yours faithfully,

**FOR ADLINE CHEM LAB LIMITED**

**(Formerly known as Kamron Laboratories Limited)**

*Kamlesh J. Laskari*

**KAMLESH J. LASKARI  
MANAGING DIRECTOR  
(DIN: 00461198)**



Encl: As above.



# ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,

Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : [info@kamronlabs.in](mailto:info@kamronlabs.in) Website: [www.kamronlabs.com](http://www.kamronlabs.com)

CIN : L24231GJ1988PLC010956



## STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31<sup>ST</sup> DECEMBER, 2021

(Rs. In Lakh)

Particulars		Quarter ended			9 Months ended (Cumulative)		Previous Year ended 31-03-2021
		31-12-2021	30-09-2021	31-12-2020	31-12-2021	31-12-2020	
(Refer Notes Below)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	8.4	0.09	163.47	71.63	425.61	632.52
2	Other income	4.89	15.94	0	20.83	0.12	0.33
3	Total Income (1+2)	13.29	16.03	163.47	92.46	425.73	633.15
4	Expenses						
	a. Cost of Materials consumed	-	-	-	-	-	-
	b. Purchases of stock-in-trade	2.66	(0.3)	102.72	34.50	181.24	233.26
	c. Changes in inventories of finished goods, work-in- progress and stock-in-trade	0.04	0.2	(17.40)	13.32	18.54	69.96
	d. Employee benefits expense	1.12	8.65	41.99	16.02	114.55	171.43
	e. Finance costs	0.00	-	0.25	0.44	0.90	3.27
	f. Depreciation & amortisation expense	25.59	25.59	28.68	76.76	86.05	102.34
	g. Other expenses	4.85	9.18	47.15	27.75	124.77	181.22
	Total Expenses	34.26	43.32	203.39	168.79	526.05	761.48
5	Profit / (Loss) before exceptional items and tax (3-4)	(20.97)	(27.29)	(39.92)	(76.33)	(100.32)	(128.33)
6	Exceptional items	-	-	-	-	-	-
7	Profit / (Loss) before tax (5+6)	(20.97)	(27.29)	(39.92)	(76.33)	(100.32)	(128.33)
8	Tax expense:						
	Current tax	-	-	-	-	-	-
	Deferred tax	-	-	-	-	-	-
9	Profit (Loss) for the period from continuing operations (7-8)	(20.97)	(27.29)	(39.92)	(76.33)	(100.32)	(128.33)
10	Profit/(loss) from discontinuing operations before Tax	-	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-	-	-
13	Profit / (Loss) for the period (9+12)	(20.97)	(27.29)	(39.92)	(76.33)	(100.32)	(128.33)



FOR, ADLINE CHEM LAB LIMITED  
(Formerly Known As Kamron Laboratories Ltd.)

*Kamrun* *Carikan*  
MANAGING DIRECTOR



# ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,  
Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : info@kamronlabs.in Website: www.kamronlabs.com

CIN : L24231GJ1988PLC010956



Particulars		Quarter ended			9 Months ended (Cumulative)		Previous Year ended 31-03-2021
		31-12-2021	30-09-2021	31-12-2020	31-12-2021	31-12-2020	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
14	Other Comprehensive Income						
	Items that will not be reclassified subsequently to profit or loss	-	-	-	-	-	-
	Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Other Comprehensive Income, net of tax	-	-	-	-	-	-
15	Total Comprehensive Income for the period (13+14)	(20.97)	(27.29)	(39.92)	(76.33)	(100.32)	(128.33)
16	Paid-up equity shares capital (Face Value per share Rs. 10/-)	585.00	585.00	585.00	585.00	585.00	585.00
17	Reserves excluding Revaluation Reserves						
18	Earnings Per Share of Rs. 10/- each (for continuing operations)						
	- Basic	(0.35)	(0.47)	(0.68)	(1.30)	(1.71)	(2.19)
	- Diluted	(0.35)	(0.47)	(0.68)	(1.30)	(1.71)	(2.19)
19	Earnings Per Share of Rs.10/- each (for discontinued operations)						
	- Basic	-	-	-	-	-	-
	- Diluted	-	-	-	-	-	-
20	Earnings Per Share of Rs. 10/- each (for discontinued & continuing operations)						
	- Basic	(0.35)	(0.47)	(0.68)	(1.30)	(1.71)	(2.19)
	- Diluted	(0.35)	(0.47)	(0.68)	(1.30)	(1.71)	(2.19)



FOR, ADLINE CHEM LAB LIMITED  
(Formerly Known As Kamron Laboratories Ltd.)

*Kamrun I. Lonkar*  
MANAGING DIRECTOR



# ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,

Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541


E-mail : [info@kamronlabs.in](mailto:info@kamronlabs.in) Website: [www.kamronlabs.com](http://www.kamronlabs.com)

CIN : L24231GJ1988PLC010956



## Notes:

1	The Company is operating only in one segment i.e. pharmaceutical products. Hence, segment reporting is not given.
2	The Company has associates with Centis Lifecare pvt ltd. And Kamron Healthcare Private Ltd.
3	Provision for taxation/deferred taxation, if any, will be made at the year end.
4	Figures, wherever required, are regrouped / rearranged.
5	The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors of Company in their respective meetings held on 14 <sup>th</sup> February, 2022.
6	The financial results are prepared in accordance with the Indian Accounting Standards (Ind AS), as applicable and guidelines issued by SEBI.
7	The name of the Company has been changed to “Adline Chem Lab Limited” from ‘Kamron Laboratories Limited’ w.e.f. 13 <sup>th</sup> October, 2021.



Date: 14<sup>th</sup> February, 2022

Place: Ahmedabad



FOR ADLINE CHEM LAB LIMITED  
(Formerly known as Kamron Laboratories Limited)

*Kamlesh J. Laskari*  
KAMLESH J. LASKARI  
MANAGING DIRECTOR  
(DIN: 00461198)



**LIMITED REVIEW REPORT****Review Report to the Board of Directors of Adline Chem Lab Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of Adline Chem Lab Limited for the period ended 31<sup>st</sup> Dec 2021, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, as amended ("the Listing Regulations"). The company was formerly known as Kamron Laboratories Ltd and the Registrar of companies Ahmedabad has generated on 13<sup>th</sup> October 2021 Certification of incorporation pursuant to change of name.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement(s). A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s Rangwala & Co.  
Chartered Accountants  
(Firm's Registration No. 115833W)



(ALIAKBAR TIMBAWALA)  
Partner  
(Membership No.180746)  
(UDIN: 22180746ACCLHW4095)



Place: Ahmedabad.  
Date: 14-02-2022.